Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:DUSP22-CECR5

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: DUSP22-CECR5
	FusionPDB ID: 24492
	FusionGDB2.0 ID: 24493
		Hgene	Tgene
	Gene symbol	DUSP22	CECR5
	Gene ID	56940	27440
	Gene name	dual specificity phosphatase 22	haloacid dehalogenase like hydrolase domain containing 5
	Synonyms	JKAP\|JSP-1\|JSP1\|LMW-DSP2\|LMWDSP2\|MKP-x\|MKPX\|VHX	CECR5
	Cytomap	6p25.3	22q11.1
	Type of gene	protein-coding	protein-coding
	Description	dual specificity protein phosphatase 22JNK-stimulating phosphatase 1JNK-stimulatory phosphatase-1MAP kinase phosphatase xepididymis secretory sperm binding proteinhomolog of mouse dual specificity phosphatase LMW-DSP2low molecular weight dual specif	haloacid dehalogenase-like hydrolase domain-containing 5cat eye syndrome chromosome region, candidate 5cat eye syndrome critical region protein 5
	Modification date	20200313	20200313
	UniProtAcc	Q9NRW4 Main function of 5'-partner protein: FUNCTION: Activates the Jnk signaling pathway. Dephosphorylates and deactivates p38 and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) (By similarity). {ECO:0000250, ECO:0000269\|PubMed:11717427}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000344450, ENST00000419235, ENST00000605035, ENST00000603290, ENST00000603453, ENST00000604971, ENST00000605315, ENST00000605863,	ENST00000480451, ENST00000399852, ENST00000155674, ENST00000336737,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	5 X 3 X 5=75	2 X 1 X 2=4
	# samples	5	2
	** MAII score	log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(2/4*10)=2.32192809488736
Fusion gene context	PubMed: DUSP22 [Title/Abstract] AND CECR5 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: DUSP22 [Title/Abstract] AND CECR5 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	DUSP22(311962)-CECR5(17630635), # samples:2
Anticipated loss of major functional domain due to fusion event.	DUSP22-CECR5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. DUSP22-CECR5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	DUSP22	GO:0035335	peptidyl-tyrosine dephosphorylation	20018849
Hgene	DUSP22	GO:0051895	negative regulation of focal adhesion assembly	20018849
Hgene	DUSP22	GO:0071364	cellular response to epidermal growth factor stimulus	20018849

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:311962/chr22:17630635)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across DUSP22 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across CECR5 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000344450	DUSP22	chr6	311962	+	ENST00000155674	CECR5	chr22	17630635	-	2237	581	443	1726	427
ENST00000344450	DUSP22	chr6	311962	+	ENST00000336737	CECR5	chr22	17630635	-	2228	581	443	1726	427
ENST00000419235	DUSP22	chr6	311962	+	ENST00000155674	CECR5	chr22	17630635	-	1872	216	78	1361	427
ENST00000419235	DUSP22	chr6	311962	+	ENST00000336737	CECR5	chr22	17630635	-	1863	216	78	1361	427

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000344450	ENST00000155674	DUSP22	chr6	311962	+	CECR5	chr22	17630635	-	0.004027081	0.99597293
ENST00000344450	ENST00000336737	DUSP22	chr6	311962	+	CECR5	chr22	17630635	-	0.004191778	0.99580824
ENST00000419235	ENST00000155674	DUSP22	chr6	311962	+	CECR5	chr22	17630635	-	0.003332726	0.9966673
ENST00000419235	ENST00000336737	DUSP22	chr6	311962	+	CECR5	chr22	17630635	-	0.003471929	0.9965281

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for DUSP22-CECR5

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
DUSP22	chr6	311962	CECR5	chr22	17630635	216	42	KVTHILSVHDSARPMLESPPTFGFLL
DUSP22	chr6	311962	CECR5	chr22	17630635	581	42	KVTHILSVHDSARPMLESPPTFGFLL

Top

Potential FusionNeoAntigen Information of DUSP22-CECR5 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

DUSP22-CECR5_311962_17630635.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:37	VHDSARPM	0.9711	0.5365	7	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:01	VHDSARPML	0.9987	0.6916	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:01	VHDSARPML	0.9975	0.8535	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:13	VHDSARPML	0.9973	0.7952	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:02	VHDSARPML	0.9973	0.8472	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:06	VHDSARPML	0.9961	0.7021	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B14:02	VHDSARPML	0.9872	0.633	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B14:01	VHDSARPML	0.9872	0.633	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:18	VHDSARPML	0.6741	0.6328	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:10	RPMLESPPTF	0.9986	0.5924	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:02	RPMLESPPTF	0.9983	0.5492	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:05	RPMLESPPTF	0.9902	0.6501	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:08	RPMLESPPTF	0.9897	0.8678	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:01	RPMLESPPTF	0.9893	0.8897	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:03	RPMLESPPTF	0.9875	0.7954	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:03	RPMLESPPTF	0.9698	0.897	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-A31:08	RPMLESPPTF	0.9428	0.5211	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:25	RPMLESPPTF	0.9351	0.9186	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:04	RPMLESPPTF	0.8925	0.9574	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:02	RPMLESPPTF	0.8925	0.9574	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:01	RPMLESPPTF	0.8858	0.9131	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-A32:13	RPMLESPPTF	0.8049	0.9253	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:01	SVHDSARPML	0.6644	0.7838	6	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B13:01	RPMLESPPTF	0.4808	0.9151	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:02	SVHDSARPML	0.3907	0.9001	6	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:01	SVHDSARPML	0.3796	0.9033	6	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B27:04	ARPMLESPPTF	0.9999	0.7055	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B13:01	ARPMLESPPTF	0.9687	0.948	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:01	LSVHDSARPML	0.6757	0.9085	5	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:09	VHDSARPM	0.9994	0.5073	7	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:05	VHDSARPM	0.9963	0.6551	7	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C04:07	VHDSARPML	0.9988	0.8373	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:12	VHDSARPML	0.9986	0.7036	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C04:10	VHDSARPML	0.9985	0.8278	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:09	VHDSARPML	0.9983	0.5084	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:05	VHDSARPML	0.9974	0.6734	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C08:15	VHDSARPML	0.997	0.9428	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C15:04	SVHDSARPM	0.9921	0.8052	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:08	SVHDSARPM	0.9921	0.7881	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:21	SVHDSARPM	0.9911	0.7991	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:19	SVHDSARPM	0.9911	0.9632	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:07	SVHDSARPM	0.9906	0.8795	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C12:12	SVHDSARPM	0.9739	0.8997	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C06:03	SVHDSARPM	0.9616	0.9729	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C12:04	SVHDSARPM	0.9589	0.9716	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:04	SVHDSARPM	0.9248	0.821	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B14:03	VHDSARPML	0.8485	0.6862	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:27	VHDSARPML	0.7511	0.9443	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:13	VHDSARPML	0.717	0.9213	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:29	VHDSARPML	0.7044	0.9249	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:08	VHDSARPML	0.6654	0.7341	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:67	VHDSARPML	0.6078	0.9521	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:80	VHDSARPML	0.6078	0.9521	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:19	VHDSARPML	0.5949	0.7402	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:10	VHDSARPML	0.5939	0.9621	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:14	SVHDSARPM	0.5662	0.9468	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:46	VHDSARPML	0.5478	0.9086	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C04:14	VHDSARPML	0.4231	0.8748	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:12	RPMLESPPTF	0.9976	0.6852	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:04	RPMLESPPTF	0.9706	0.5106	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:05	RPMLESPPTF	0.9688	0.869	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:12	RPMLESPPTF	0.8925	0.9574	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:07	RPMLESPPTF	0.8714	0.8287	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B42:02	RPMLESPPTF	0.8522	0.7578	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B42:01	RPMLESPPTF	0.8317	0.7543	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:04	RPMLESPPTF	0.8228	0.9434	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:10	RPMLESPPTF	0.7963	0.9335	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:05	SVHDSARPML	0.3621	0.7547	6	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:05	ARPMLESPPTF	0.9999	0.9359	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B27:14	ARPMLESPPTF	0.9999	0.5104	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:95	ARPMLESPPTF	0.9999	0.7414	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:27	ARPMLESPPTF	0.9997	0.9353	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:29	ARPMLESPPTF	0.9995	0.9194	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:67	ARPMLESPPTF	0.9987	0.9553	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:80	ARPMLESPPTF	0.9987	0.9553	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:13	ARPMLESPPTF	0.9985	0.9121	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:19	ARPMLESPPTF	0.9984	0.8332	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:46	ARPMLESPPTF	0.9983	0.9273	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:10	ARPMLESPPTF	0.9971	0.9641	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:11	HDSARPML	0.998	0.6252	8	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:09	VHDSARPM	0.9866	0.5237	7	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:11	VHDSARPM	0.9733	0.5434	7	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C04:01	VHDSARPML	0.9988	0.8373	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:31	VHDSARPML	0.9987	0.6955	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:02	VHDSARPML	0.9985	0.7938	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C18:01	VHDSARPML	0.9975	0.8196	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:05	VHDSARPML	0.9975	0.8535	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C08:02	VHDSARPML	0.997	0.9428	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:13	SVHDSARPM	0.9959	0.6535	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:04	SVHDSARPM	0.9936	0.9711	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:03	SVHDSARPM	0.9936	0.9711	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:02	SVHDSARPM	0.9921	0.9263	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C15:09	SVHDSARPM	0.9921	0.8052	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:08	SVHDSARPM	0.9915	0.7657	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:67	SVHDSARPM	0.9913	0.9571	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:43	SVHDSARPM	0.99	0.77	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:11	SVHDSARPM	0.9881	0.7769	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:05	SVHDSARPM	0.9811	0.8409	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:17	SVHDSARPM	0.9808	0.9167	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C16:04	SVHDSARPM	0.9745	0.9158	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C12:03	SVHDSARPM	0.9735	0.945	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C12:02	SVHDSARPM	0.9686	0.9238	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-A25:01	SVHDSARPM	0.968	0.5453	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:06	SVHDSARPM	0.8259	0.9705	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C06:06	VHDSARPML	0.7859	0.974	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C16:01	SVHDSARPM	0.7611	0.9573	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C02:10	SVHDSARPM	0.7609	0.9263	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C02:02	SVHDSARPM	0.7609	0.9263	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:11	VHDSARPML	0.7582	0.6094	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:30	SVHDSARPM	0.7385	0.6494	6	15
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C03:67	VHDSARPML	0.7338	0.9722	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:17	VHDSARPML	0.6953	0.9669	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:02	VHDSARPML	0.6078	0.9521	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C04:04	VHDSARPML	0.5957	0.826	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:04	VHDSARPML	0.5742	0.9398	7	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:09	RPMLESPPTF	0.9988	0.5188	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B07:22	RPMLESPPTF	0.9983	0.5492	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:17	RPMLESPPTF	0.9911	0.8076	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:30	RPMLESPPTF	0.9911	0.8076	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:77	RPMLESPPTF	0.9893	0.8897	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:23	RPMLESPPTF	0.9888	0.891	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:11	RPMLESPPTF	0.9808	0.9052	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:20	RPMLESPPTF	0.9721	0.9084	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:13	RPMLESPPTF	0.9648	0.9002	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:28	RPMLESPPTF	0.9599	0.9148	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:13	RPMLESPPTF	0.9532	0.7481	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:39	RPMLESPPTF	0.9373	0.8467	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:24	RPMLESPPTF	0.935	0.906	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:43	RPMLESPPTF	0.9253	0.8934	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:08	RPMLESPPTF	0.9225	0.8917	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:11	RPMLESPPTF	0.921	0.8824	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B35:09	RPMLESPPTF	0.8925	0.9574	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:27	RPMLESPPTF	0.8899	0.9245	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:33	RPMLESPPTF	0.8858	0.9131	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:34	RPMLESPPTF	0.8858	0.9131	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:125	RPMLESPPTF	0.8858	0.9131	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-A32:01	RPMLESPPTF	0.8777	0.9767	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:135	RPMLESPPTF	0.8773	0.9292	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:24	RPMLESPPTF	0.8769	0.9337	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:50	RPMLESPPTF	0.8731	0.9474	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:35	RPMLESPPTF	0.8477	0.9296	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B67:01	RPMLESPPTF	0.8158	0.7853	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:30	RPMLESPPTF	0.7883	0.9418	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B15:73	RPMLESPPTF	0.7319	0.9484	12	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:11	SVHDSARPML	0.6994	0.6325	6	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:05	SVHDSARPML	0.3796	0.9033	6	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B27:10	ARPMLESPPTF	0.9999	0.7626	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B27:06	ARPMLESPPTF	0.9999	0.7648	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:01	ARPMLESPPTF	0.9999	0.7203	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:22	ARPMLESPPTF	0.999	0.8235	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-C07:02	ARPMLESPPTF	0.9987	0.9553	11	22
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B39:11	LSVHDSARPML	0.9386	0.6652	5	16
DUSP22-CECR5	chr6	311962	chr22	17630635	581	HLA-B38:05	LSVHDSARPML	0.6757	0.9085	5	16

Top

Potential FusionNeoAntigen Information of DUSP22-CECR5 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of DUSP22-CECR5

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
9147	SVHDSARPMLESPP	DUSP22	CECR5	chr6	311962	chr22	17630635	581

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of DUSP22-CECR5

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	9147	SVHDSARPMLESPP	-7.15543	-7.26883
HLA-B14:02	3BVN	9147	SVHDSARPMLESPP	-4.77435	-5.80965
HLA-B52:01	3W39	9147	SVHDSARPMLESPP	-6.80875	-6.92215
HLA-B52:01	3W39	9147	SVHDSARPMLESPP	-4.20386	-5.23916
HLA-A11:01	4UQ2	9147	SVHDSARPMLESPP	-7.5194	-8.5547
HLA-A11:01	4UQ2	9147	SVHDSARPMLESPP	-6.9601	-7.0735
HLA-A24:02	5HGA	9147	SVHDSARPMLESPP	-7.52403	-7.63743
HLA-A24:02	5HGA	9147	SVHDSARPMLESPP	-5.82433	-6.85963
HLA-B27:05	6PYJ	9147	SVHDSARPMLESPP	-3.28285	-4.31815
HLA-B44:05	3DX8	9147	SVHDSARPMLESPP	-5.91172	-6.94702
HLA-B44:05	3DX8	9147	SVHDSARPMLESPP	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of DUSP22-CECR5

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
DUSP22-CECR5	chr6	311962	chr22	17630635	11	22	ARPMLESPPTF	TTGGAGAGCCCACCCACCTTTGGGTTCCTGTTG
DUSP22-CECR5	chr6	311962	chr22	17630635	12	22	RPMLESPPTF	GAGAGCCCACCCACCTTTGGGTTCCTGTTG
DUSP22-CECR5	chr6	311962	chr22	17630635	5	16	LSVHDSARPML	GATAGTGCCAGGCCTATGTTGGAGAGCCCACCC
DUSP22-CECR5	chr6	311962	chr22	17630635	6	15	SVHDSARPM	AGTGCCAGGCCTATGTTGGAGAGCCCA
DUSP22-CECR5	chr6	311962	chr22	17630635	6	16	SVHDSARPML	AGTGCCAGGCCTATGTTGGAGAGCCCACCC
DUSP22-CECR5	chr6	311962	chr22	17630635	7	15	VHDSARPM	GCCAGGCCTATGTTGGAGAGCCCA
DUSP22-CECR5	chr6	311962	chr22	17630635	7	16	VHDSARPML	GCCAGGCCTATGTTGGAGAGCCCACCC
DUSP22-CECR5	chr6	311962	chr22	17630635	8	16	HDSARPML	AGGCCTATGTTGGAGAGCCCACCC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of DUSP22-CECR5

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SKCM	DUSP22-CECR5	chr6	311962	ENST00000344450	chr22	17630635	ENST00000155674	TCGA-DA-A1I8-06A

Top

Potential target of CAR-T therapy development for DUSP22-CECR5

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to DUSP22-CECR5

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to DUSP22-CECR5

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)